PM
RLAY icon

Prosight Management’s Relay Therapeutics RLAY Stock Holding History

Prosight Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-385,000
Closed -$2.51M – 58
2024
Q2 		$2.51M Sell
385,000
-65,000
-14% -$444K 0.75% 27
2024
Q1 		$3.73M Buy
+450,000
New +$4.39M 1.04% 26

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Prosight Management's RLAY Position: Q3 2024 in Review

Prosight Management sold out of Relay Therapeutics (RLAY) in Q3 2024, closing a stake of 385,000 shares — an estimated $2.51M sold.

Prosight Management first reported a position in RLAY in Q1 2024 and held it in 2 quarters. The position peaked at $3.73M in Q1 2024. 195 funds tracked by Wall St. Rank hold RLAY as of Q3 2024.

  • Prosight Management reported no remaining Relay Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Prosight Management sold 385,000 Relay Therapeutics shares in Q3 2024, an estimated $2.51M.
  • Prosight Management first reported a position in Relay Therapeutics in Q1 2024 and held it in 2 quarters.
  • Prosight Management's Relay Therapeutics position peaked at $3.73M in Q1 2024.
  • 195 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2024.

Based on Prosight Management's 13F filing for Q3 2024, filed 14 Nov 2024.